Overview
Biofourmis delivers hospital-level care at home by combining a digital health platform with biosensors and deep learning. Hospitals, pharma firms, and patients use its predictive analytics to remotely monitor patients, track vital data, and personalize care. The platform works through wearable sensors that collect data and AI models that continuously analyze it to predict medical events and guide interventions, enabling proactive care outside the hospital. Compared to traditional remote monitoring, Biofourmis focuses on deep learning-based predictive analytics and end-to-end care delivery, plus partnerships with pharmaceutical companies to optimize drug efficacy and outcomes. The company aims to prevent costly health events, improve patient outcomes, and extend hospital-level care into home settings by selling subscriptions and service contracts to healthcare systems and collaborating with drug developers.
Work here?Claim your company
Simplify's take
What believers are saying
- November 2026 reports show $20 million top-up funding from Intel Capital.
- Biofourmis won Novartis heart-failure collaboration for Southeast Asia, with global expansion optionality.
- Lee Health pilot expands Hospital at Home, validating Biofourmis inside a real health system.
What critics are saying
- ActiGraph bought Biofourmis Connect in January 2025, shrinking life-science revenue and focus.
- June 2025 layoffs cut 120 employees globally, signaling cost pressure and organizational strain.
- Two business lines remain vulnerable: payer reimbursement cuts and hospital-at-home contract losses.
What makes Biofourmis unique
- BiofourmisCare spans hospital-at-home, transitional care, and chronic monitoring in one workflow.
- October 2024 CopilotIQ merger unified pre-surgery, acute, post-acute, and chronic in-home care.
- Epic showroom integration gives Biofourmis live EHR connectivity across remote patient monitoring.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards